Navigation Links
Study Compares Risk With Two Diabetes Drugs
Date:8/24/2010

DALLAS, Aug. 24 /PRNewswire-USNewswire/ -- In contrast to previous reports, the risks of the composite endpoint of heart attack, heart failure, both, or death were the same – about 4 percent – for patients taking the diabetes drugs rosiglitazone or pioglitazone, according to a study published in the American Heart Association journal Circulation: Cardiovascular Quality and Outcomes.

(Logo: http://photos.prnewswire.com/prnh/20100222/AHSALOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100222/AHSALOGO)

"This study provides patients and their doctors with another source of information about rosiglitazone and pioglitazone (sold as Avandia and Actos, respectively) as they determine the best therapy for diabetes patients," said Debra Wertz, Pharm.D., lead author and outcomes research manager at HealthCore, Inc., the research subsidiary of health insurance company WellPoint, Inc.

This study evaluated more than 36,000 diabetes patients. Of the 28,938 patients who were propensity-score matched, a methodology used to provide an estimation of treatment-effects that is as unbiased as possible, 602 patients taking rosiglitazone and 599 taking pioglitazone over a 33-month period suffered either a heart attack, heart failure, both, or died. This translates to about 4 percent of all patients taking either medication. The individual specific adverse events were also not significantly different between the two groups, and were:

  • Heart attack – 96 patients on rosiglitazone and 121 patients on pioglitazone;
  • Heart failure – 265 patients taking rosiglitazone and 243 taking pioglitazone;
  • Heart attack and heart failure – 24 patients on rosiglitazone and 18 on pioglitazone; and
  • Death –
    '/>"/>

  • SOURCE American Heart Association
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
    2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
    3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
    5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
    6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
    7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
    8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
    9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
    10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
    11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/3/2015)... -- Biosensors International Group, Ltd. ("Biosensors" or the ... a developer, manufacturer and marketer of innovative medical ... fiscal quarter ended 30 June 2015 ("Q1 FY16"). ... , Biosensors continued to make ... by lower operating expenses and operational improvement. Operating ...
    (Date:8/3/2015)... , Aug. 3, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... host its Second Quarter 2015 Investor Conference Call and ... The call will cover an update on ... quarter 2015 financials. A press release detailing the information ... the afternoon of Monday, August 10. Investors and the ...
    (Date:8/3/2015)... , Aug. 3, 2015  Charleston Laboratories, Inc., ... its second clinical development program with a Phase ... CL-H1T contains fast-dissolving promethazine and ... as a treatment for migraine headache pain and ... "Many patients with migraine headaches also suffer from ...
    Breaking Medicine Technology:Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2
    ... 2011 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China ... CSKI ), a leading fully integrated pharmaceutical company in ... shareholder letter from Mr. Yanqing Liu, the Company,s Chairman ... full text of this shareholder letter is as follows: ...
    ... 21, 2011 VIVUS, Inc. (Nasdaq: VVUS ) ... Food and Drug Administration (FDA) for the New Drug Application ... obesity.  The meeting occurred on January 19th at the FDA,s ... the FDA and VIVUS, management and consultants.  At this meeting ...
    Cached Medicine Technology:Shareholder Letter from Chairman of China Sky One Medical 2Shareholder Letter from Chairman of China Sky One Medical 3Shareholder Letter from Chairman of China Sky One Medical 4VIVUS Provides Regulatory Update on QNEXA NDA 2VIVUS Provides Regulatory Update on QNEXA NDA 3
    (Date:8/3/2015)... ... August 03, 2015 , ... Dental practice in Los ... in need. Most people know that general health emergencies, such as broken arms or ... of people know where to turn to during a dental emergency. This is important, ...
    (Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... Physician Leadership ® and Navigant Center for Healthcare Research and Policy Analysis show ... Fifty-five percent of respondents said they agreed or strongly agreed that the controversial ...
    (Date:8/3/2015)... ... August 03, 2015 , ... The U.S. Food and Drug Administration (FDA) ... similar to deoxycholic acid, which occurs naturally in the body and helps absorb and ... this area of the body. These are invasive procedures and very expensive for most ...
    (Date:8/3/2015)... ... 2015 , ... Illinois Health & Science (IHS) has completed the purchase of ... all of IBAM NA’s cyclotron sites and research and development facilities. , ... as well as a large manufacturing hub in Noblesville, Indiana,” said Ken Smithmier, President ...
    (Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... Government Programs, with accountability for overall performance of the company’s Medicare and Federal ... focus of Cambia’s strategy to deliver better health for members. In this role, ...
    Breaking Medicine News(10 mins):Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2
    ... chapping, experts advise , SATURDAY, Dec. 26 (HealthDay News) ... humidity, and the air inside is heated and dry, you ... say. , To prevent scaling, flaking and itching, pay special ... a cream-based moisturizer every day, recommends Dr. Anjali Dahiya, a ...
    ... Christmas trees and holiday distractions raise risk of a blaze ... on beautifully set tables and yule logs burning make for ... the risk of fires, experts say. , Alcohol and parties ... safety, said Dr. Roger Yurt, director of the Hearst Burn ...
    ... to those in pot that increase the response to sweets ... some light on the "munchies" -- the desire that pot ... the active ingredient in marijuana, is similar to substances known ... and enhance the perception of sweet foods, researchers say. , ...
    ... Mouse study holds promise for humans with hereditary disease ... reporting that they,ve discovered a molecular switch that appears ... in mice. , An estimated one out of every ... and disrupts a person,s ability to walk, talk, think ...
    ... , WASHINGTON, Dec. 24 This ... final passage of HR 3590, the so-called "Patient Protection and ... Research Council President Tony Perkins made the following comments: , ... debate in the Senate, but it,s far from the end ...
    ... Bill Must Be Improved: Anti-Choice Provisions in Senate and House ... Affordable , WASHINGTON, Dec. 24 The following ... for Women & Families: , "The Senate took a historic ... morning by passing comprehensive reform that will cover 31 million ...
    Cached Medicine News:Health News:Skin Needs Protection From Winter Weather 2Health News:Keep Fire Safety in Mind as You Celebrate 2Health News:Scientists Find Molecular Switch Related to Huntington's 2Health News:FRC Statement on the Christmas Eve Passage of the Health Care 'Reform' Bill 2Health News:Senate Passage of Health Reform a Historic Milestone, National Partnership President Says 2
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: